Foghorn Therapeutics (NASDAQ:FHTX - Get Free Report ) is projected to release its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Foghorn Therapeutics to post earnings of ($0.28) per share and revenue of $7.9410 million for the quarter. Interested persons can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 9:30 AM ET.
Get Foghorn Therapeutics SMS alerts:
Sign Up
Foghorn Therapeutics (NASDAQ:FHTX - Get Free Report ) last issued its quarterly earnings results on Wednesday, March 11th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.04). The company had revenue of $9.25 million for the quarter, compared to the consensus estimate of $9.50 million. On average, analysts expect Foghorn Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Foghorn Therapeutics Price Performance Shares of NASDAQ FHTX opened at $4.64 on Wednesday. Foghorn Therapeutics has a 1 year low of $3.27 and a 1 year high of $6.95. The stock has a market cap of $272.41 million, a P/E ratio of -3.97 and a beta of 2.97. The firm has a 50-day moving average of $5.13 and a 200 day moving average of $5.05.
Institutional Trading of Foghorn Therapeutics Several large investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. grew its position in Foghorn Therapeutics by 4.0% during the third quarter. Raymond James Financial Inc. now owns 2,462,488 shares of the company's stock valued at $12,042,000 after buying an additional 95,196 shares during the period. Vanguard Group Inc. lifted its holdings in Foghorn Therapeutics by 0.8% during the third quarter. Vanguard Group Inc. now owns 1,899,457 shares of the company's stock valued at $9,288,000 after purchasing an additional 14,784 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Foghorn Therapeutics by 16.9% during the second quarter. Geode Capital Management LLC now owns 807,674 shares of the company's stock valued at $3,797,000 after purchasing an additional 116,979 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Foghorn Therapeutics by 151.8% during the fourth quarter. Renaissance Technologies LLC now owns 297,736 shares of the company's stock valued at $1,608,000 after purchasing an additional 179,500 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its holdings in Foghorn Therapeutics by 46.2% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 269,186 shares of the company's stock valued at $1,454,000 after purchasing an additional 85,123 shares in the last quarter. 61.55% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In FHTX has been the subject of several recent analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $13.00 target price on shares of Foghorn Therapeutics in a report on Tuesday, March 10th. Wall Street Zen cut shares of Foghorn Therapeutics from a "buy" rating to a "hold" rating in a report on Saturday, March 14th. Jefferies Financial Group reaffirmed a "buy" rating on shares of Foghorn Therapeutics in a report on Thursday, March 12th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Foghorn Therapeutics in a report on Tuesday, April 21st. Finally, Wedbush reaffirmed an "outperform" rating and issued a $10.00 target price on shares of Foghorn Therapeutics in a report on Thursday, March 12th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $11.13.
Read Our Latest Analysis on Foghorn Therapeutics
Foghorn Therapeutics Company Profile (
Get Free Report )
Foghorn Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of novel epigenetic therapies for cancer. The company leverages its proprietary Targeted Protein Discovery Platform to identify and design small-molecule inhibitors that modulate chromatin regulatory proteins involved in tumor growth and survival. By targeting the mechanisms that control gene expression, Foghorn seeks to address unmet needs in oncology through precision medicine.
The company's lead candidate, FHD-286, is a selective inhibitor of variant SWI/SNF chromatin remodeling complexes and is currently being evaluated in Phase 1 clinical trials for patients with solid tumors harboring specific SMARCA2 and SMARCA4 alterations.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Foghorn Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Foghorn Therapeutics wasn't on the list.
While Foghorn Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
